Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

CYCC Stock - Cyclacel Pharmaceuticals Stock Trading


home / stock / cycc

CYCC CYCC Quote CYCC Short CYCC News CYCC Articles CYCC Message Board

MWN AI Summary *

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. Founded in 1996 and headquartered in Durham, North Carolina, Cyclacel concentrates on harnessing the power of cell cycle and transcriptional regulation to create novel cancer therapies.

The company's lead product candidate,apasertib, is a selective inhibitor of cyclin-dependent kinases (CDKs), and is designed to target various malignancies including leukemia and solid tumors. Cyclacel is also advancing its other pipeline candidates, such as CYC140, a potent and selective inhibitor of CDK2, which has potential therapeutic applications in several cancer types.

Cyclacel Pharmaceuticals is actively engaged in clinical trials to determine the safety and efficacy of its drug candidates. These trials aim to expand the understanding of how CDK inhibitors can improve patient outcomes, particularly in chemotherapy-resistant cancers. The company's strategy includes partnering with academic institutions and other biotech firms to fast-track research and development.

As of October 2023, Cyclacel continues to attract investor interest due to its focused approach on CDK inhibitors and the potential of its product candidates. The biotechnology sector has seen increased investment as advancements in personalized medicine create new opportunities for growth. However, investors should note that the clinical-stage nature of Cyclacel’s business carries inherent risks, including the potential for setbacks in clinical trials or regulatory approvals.

Overall, Cyclacel Pharmaceuticals Inc. represents a potentially promising player in the oncology landscape, with a strong emphasis on innovation and scientific rigor. As the company progresses through its clinical trials, its prospects in the biopharmaceutical arena will depend on successful outcomes and strategic collaborations.

MWN AI Analysis *

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) operates as a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. As of October 2023, Cyclacel is advancing several promising candidates through clinical trials, with a particular focus on its drugs targeting various forms of cancer, including hematological malignancies.

Analyzing the current market position of Cyclacel, several factors come into play. The company’s product pipeline consists of direct inhibitors of cell cycle and transcriptional regulation, which are crucial in cancer progression. Among their notable candidates is CYC065, which has shown potential in targeting advanced solid tumors and hematological cancers. As new data emerges from ongoing clinical trials, investor sentiment could swing significantly based on trial outcomes, making it essential to keep a close watch on any upcoming announcements.

From a financial perspective, Cyclacel continues to navigate the challenging landscape of biotech financing. Historically, smaller biotechnology firms often experience volatility in stock prices, driven by the binary outcomes of clinical trials. Thus, investors should assess their risk tolerance carefully when considering an investment in CYCC. The company has also been involved in securing funding, which is vital for sustaining operations and furthering its clinical objectives.

Market sentiment around biotech stocks often fluctuates, influenced by broader trends in healthcare, regulatory approval processes, and competition. As Cyclacel advances its clinical programs, it will be critical to monitor both the competitive landscape and market conditions. Furthermore, strategic partnerships or collaborations could enhance Cyclacel's market presence and provide additional funding avenues.

In conclusion, investors interested in Cyclacel Pharmaceuticals should stay informed of clinical trial updates and be mindful of the inherent risks. Given the volatility and potential for significant returns, a cautious approach combined with an active monitoring strategy may serve investors well in this dynamic sector.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

Quote | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

Last:$3.71
Change Percent: 1.9%
Open:$4.12
Close:$3.71
High:$4.1732
Low:$3.68
Volume:74,189
Last Trade Date Time:07/11/2025 03:31:47 pm

News | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

  • Market Headliners- July 7, 2025

    2025-07-07 09:45:53 ET DENVER, Colo., Jul 07, 2025 ( 247marketnews.com )- In a bold move to accelerate its national expansion, Venu (NYSE:VENU) appointed Terri Liebler as President of Growth and Strategy , a newly created executive role signaling the company’s intent ...

    • July 07, 2025 09:45:53 am

    • |
    • 24/7 Market News
    • |
      • CYCC Stock
      • CYCC Quote
      • CYCC Short
      • CYCC News
      • CYCC Articles
      • CYCC Message Board
  • CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

    Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to ...

    • July 07, 2025 06:00:00 am

    • |
    • GlobeNewswire
    • |
      • CYCC Stock
      • CYCC Quote
      • CYCC Short
      • CYCC News
      • CYCC Articles
      • CYCC Message Board

Message Board Posts | Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

Subject By Source When
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces K whytestocks investorshangout 01/05/2023 8:30:46 PM
Sar Pas, Cytobeliever investorshub 12/06/2022 9:37:42 PM
So what do you have to say now? Cytobeliever investorshub 11/22/2022 4:50:50 PM
whytestocks: $CYCC News Article - Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 whytestocks investorshangout 09/21/2022 2:45:48 PM
znewcar1: CYCC 26% v10,2M c1.68 f9,994M H1.72 PMH1.99 flushed S1.42 then crawled out EOD znewcar1 investorshangout 08/12/2022 2:02:07 AM

MWN AI FAQ **

What recent developments have been made by Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) regarding their clinical trials and product pipeline?

Recently, Cyclacel Pharmaceuticals Inc. announced positive interim results from its clinical trials for both its lead product candidate, fadraciclib, for treating various cancers and the advancement of its pipeline focused on innovative therapies targeting cell cycle disturbances.

How does Cyclacel Pharmaceuticals Inc. CYCC plan to finance its ongoing research and development efforts in the competitive biotech landscape?

Cyclacel Pharmaceuticals Inc. (CYCC) plans to finance its ongoing research and development efforts through a combination of strategic partnerships, potential grants, and exploring various funding options, including public or private financing, to support its innovative pipeline.

What are the key partnerships currently in place for Cyclacel Pharmaceuticals Inc. CYCC, and how might they impact the company's growth trajectory?

Cyclacel Pharmaceuticals Inc. has strategic collaborations with major institutions and pharmaceutical companies that enhance its clinical development capabilities and access to resources, potentially accelerating drug discovery, improving financial stability, and driving its growth trajectory.

In light of market conditions, what is the investment outlook for Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) over the next year?

The investment outlook for Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) over the next year remains cautiously optimistic, driven by potential advancements in their clinical trials and the overall biotech sector's volatility amidst fluctuating market conditions.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get CYCC Alerts

News, Short Squeeze, Breakout and More Instantly...

Cyclacel Pharmaceuticals Inc. Company Name:

CYCC Stock Symbol:

NASDAQ Market:

1.9% G/L:

$3.71 Last:

74,189 Volume:

$4.12 Open:

$3.71 Close:

Cyclacel Pharmaceuticals Inc. Website:

Cyclacel Pharmaceuticals Inc. Logo

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
RECENT CYCC NEWS
  • CYCC - Market Headliners- July 7, 2025

    2025-07-07 09:45:53 ET DENVER, Colo., Jul 07, 2025 ( 247marketnews.com )- In a bold move to accelerate its national expansion, Venu (NYSE:VENU) appointed Terri Liebler as President of Growth and Strategy , a newly created executive role signaling the company’s intent ...

  • CYCC - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

    Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to ...

  • CYCC - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

    - Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Important Investor News Alert (NASDAQ: CVKD)

 Logo

  • CVKD - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

    LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per ev...

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get CYCC Alerts

Get CYCC Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1